In the SARS‐CoV‐2 era, do we need to be afraid of obinutuzumab?
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19786 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Joleen Choy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19, Lymphoma, Follicular, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In their paper, Pinto et al. report findings from the Italian URBAN study; an ambispective, observational, multicentre study evaluating the safety and efficacy of obinutuzumab‐based therapy for advanced stage follicular lymphoma (FL) in routine practice. The URBAN substudy reported here examined severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) outcomes in 299 patients with treatment‐naïve advanced stage FL, treated with obinutuzumab‐based chemoimmunotherapy and maintenance. The study began enrolling in September 2019, continuing enrolment throughout the pandemic, with cut‐off for the current analysis of 31 January 2022; thus, it provides unique insights into various pandemic phases, including the impact of administration of SARS‐CoV‐2 vaccination. Commentary on: Pinto et al. Exposure to obinutuzumab does not affect outcomes of SARS‐CoV‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma. Br J Haematol 2024; 205: 2219‐2227 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
- University of Western Australia, Nedlands, Western Australia, Australia.
ORCID-Profile: Joleen Choy, Katharine L Lewis
Zitieren
APA
Choy, J., & Lewis, K. L. (2024). In the SARS‐CoV‐2 era, do we need to be afraid of obinutuzumab?. British Journal of Haematology. https://doi.org/10.1111/bjh.19786
Vancouver
Choy J, Lewis KL. In the SARS‐CoV‐2 era, do we need to be afraid of obinutuzumab?. British Journal of Haematology. 2024. doi:10.1111/bjh.19786
BibTeX
@article{Choy2024,
author = {Choy, Joleen and Lewis, Katharine L},
title = {In the SARS‐CoV‐2 era, do we need to be afraid of obinutuzumab?},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19786}
}
EUVIMED